Literature DB >> 30790214

Post-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach.

Laura E Jonkman1, Boyd Kenkhuis2,3, Jeroen J G Geurts4, Wilma D J van de Berg4.   

Abstract

In this review, combined post-mortem brain magnetic resonance imaging (MRI) and histology studies are highlighted, illustrating the relevance of translational approaches to define novel MRI signatures of neuropathological lesions in neuroinflammatory and neurodegenerative disorders. Initial studies combining post-mortem MRI and histology have validated various MRI sequences, assessing their sensitivity and specificity as diagnostic biomarkers in neurologic disease. More recent studies have focused on defining new radiological (bio)markers and implementing them in the clinical (research) setting. By combining neurological and neuroanatomical expertise with radiological development and pathological validation, a cycle emerges that allows for the discovery of novel MRI biomarkers to be implemented in vivo. Examples of this cycle are presented for multiple sclerosis, Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Some applications have been shown to be successful, while others require further validation. In conclusion, there is much to explore with post-mortem MRI and histology studies, which can eventually be of high relevance for clinical practice.

Entities:  

Keywords:  Alzheimer’s disease; Biomarkers; Histology; MRI; Multiple sclerosis; Parkinson’s disease

Mesh:

Year:  2019        PMID: 30790214      PMCID: PMC6426886          DOI: 10.1007/s12264-019-00342-3

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  106 in total

Review 1.  Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution.

Authors:  P M Matthews; D L Arnold
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Cortical lesions in multiple sclerosis.

Authors:  D Kidd; F Barkhof; R McConnell; P R Algra; I V Allen; T Revesz
Journal:  Brain       Date:  1999-01       Impact factor: 13.501

4.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia.

Authors:  C R Jack; D W Dickson; J E Parisi; Y C Xu; R H Cha; P C O'Brien; S D Edland; G E Smith; B F Boeve; E G Tangalos; E Kokmen; R C Petersen
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

5.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy.

Authors:  H Benveniste; G Einstein; K R Kim; C Hulette; G A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

6.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

Authors:  J W Peterson; L Bö; S Mörk; A Chang; B D Trapp
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

Review 7.  Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.

Authors:  C Lucchinetti; W Brück; J Noseworthy
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

8.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

Authors:  P Damier; E C Hirsch; Y Agid; A M Graybiel
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

9.  Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds.

Authors:  F Fazekas; R Kleinert; G Roob; G Kleinert; P Kapeller; R Schmidt; H P Hartung
Journal:  AJNR Am J Neuroradiol       Date:  1999-04       Impact factor: 3.825

10.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.

Authors:  Chris Zarow; Scott A Lyness; James A Mortimer; Helena C Chui
Journal:  Arch Neurol       Date:  2003-03
View more
  6 in total

Review 1.  Biomarkers for Parkinson's Disease: How Good Are They?

Authors:  Tianbai Li; Weidong Le
Journal:  Neurosci Bull       Date:  2019-10-23       Impact factor: 5.203

2.  Post-mortem correlates of Virchow-Robin spaces detected on in vivo MRI.

Authors:  Lukas Haider; Simon Hametner; Verena Endmayr; Stephanie Mangesius; Andrea Eppensteiner; Josa M Frischer; Juan Eugenio Iglesias; Frederik Barkhof; Gregor Kasprian
Journal:  J Cereb Blood Flow Metab       Date:  2022-05-17       Impact factor: 6.960

3.  Axonal Iron Transport might Contribute to Iron Deposition in Parkinson's Disease.

Authors:  Leilei Chen; Chong Li; Junxia Xie
Journal:  Neurosci Bull       Date:  2020-09-22       Impact factor: 5.203

4.  Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology.

Authors:  Sarah E Burke; Jeffrey S Phillips; Christopher A Olm; Claire S Peterson; Phillip A Cook; James C Gee; Edward B Lee; John Q Trojanowski; Lauren Massimo; David J Irwin; Murray Grossman
Journal:  Neurobiol Aging       Date:  2022-02-24       Impact factor: 5.133

5.  Cortical and Subcortical Grey Matter Abnormalities in White Matter Hyperintensities and Subsequent Cognitive Impairment.

Authors:  Wenhao Zhu; Hao Huang; Shiqi Yang; Xiang Luo; Wenzhen Zhu; Shabei Xu; Qi Meng; Chengchao Zuo; Yong Liu; Wei Wang
Journal:  Neurosci Bull       Date:  2021-04-07       Impact factor: 5.203

6.  Myelin Quantification in White Matter Pathology of Progressive Multiple Sclerosis Post-Mortem Brain Samples: A New Approach for Quantifying Remyelination.

Authors:  Marije J D Huitema; Eva M M Strijbis; Antonio Luchicchi; John G J M Bol; Jason R Plemel; Jeroen J G Geurts; Geert J Schenk
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.